SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
Kapadia SU, Simon ID, Rose JK.
Kapadia SU, et al.
Virology. 2008 Jun 20;376(1):165-72. doi: 10.1016/j.virol.2008.03.002. Epub 2008 Apr 8.
Virology. 2008.
PMID: 18396306
Free PMC article.
A SARS vaccine based on a live-attenuated vesicular stomatitis virus (VSV) recombinant expressing the SARS-CoV S protein provides long-term protection of immunized mice from SARS-CoV infection (Kapadia, S.U., Rose, J. K., Lamirande, E., Vogel, L., Subbarao, K., Robe …
A SARS vaccine based on a live-attenuated vesicular stomatitis virus (VSV) recombinant expressing the SARS-CoV S protein provides long-term …